Year
17 Jan 2019
EpiEndo is pleased to announce that we have successfully closed a financing round of ISK 110 million (800.000 EUR).
01 Sep 2018
EpiEndo is pleased to welcome Fredrik Lehmann to our team as the new CEO of EpiEndo.
29 Jun 2018
EpiEndo Pharmaceuticals has signed a grant agreement today with the Icelandic Technology Development Fund.
18 Mar 2017
The following were appointed to the board of EpiEndo Pharmaceuticals at the Annual General Meeting on 17 March 2017.
31 Jan 2017
EpiEndo Pharmaceuticals are proud to announce that we have been granted a Horizon 2020 grant from the European Union (EU) for the feasibility of the development of our compounds.
25 May 2016
EpiEndo Pharmaceuticals is proud to announce that we have received a 3 year grant from the Technology Development Fund, which is managed by RANNÍS - The Icelandic Centre for Research - and aims to support research and development activities and endorsing innovation in Icelandic technology.
11 Oct 2014
EpiEndo Pharmaceuticals are proud to announce our new partnership with Recipharm, a Swedish Contract Development and Manufacturing Organisation (CDMO). EpiEndo and Recipharm will be collaborating in the synthesis of our novel compound, which will be led by Fredrik Lehman, our CMC Director and General Manager at Recipharm.
02 Jun 2014
EpiEndo Pharmaceuticals has been granted a 2 year grant by RANNÍS - The Icelandic Centre for Research - for compound research and patent applications, as well as to initiate studies that will be the foundations of clinical testing and development of novel drugs for the treatment of airway diseases.
01 Jan 1970
REYKJAVIK, ICELAND – 23 October 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, has completed its proof of pharmacology study for lead asset EP395 in healthy volunteers.